Single‐dose immunisation with a multimerised SARS‐CoV‐2 receptor binding domain (RBD) induces an enhanced and protective response in mice

The COVID‐19 pandemic, caused by the SARS‐CoV‐2 coronavirus, has triggered a worldwide health emergency. Here, we show that ferritin‐like Dps from hyperthermophilic Sulfolobus islandicus, covalently coupled with SARS‐CoV‐2 antigens via the SpyCatcher system, forms stable multivalent dodecameric vaccine nanoparticles that remain intact even after lyophilisation. Immunisation experiments in mice demonstrated that the SARS‐CoV‐2 receptor binding domain (RBD) coupled to Dps (RBD‐S‐Dps) elicited a higher antibody titre and an enhanced neutralising antibody response compared to monomeric RBD. A single immunisation with RBD‐S‐Dps completely protected hACE2‐expressing mice from serious illness and led to viral clearance from the lungs upon SARS‐CoV‐2 infection. Our data highlight that multimerised SARS‐CoV‐2 subunit vaccines are a highly efficacious modality, particularly when combined with an ultra‐stable scaffold.

[1]  Rachel L. Spreng,et al.  Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses , 2021, Nature.

[2]  Jiecan Zhou,et al.  The Mechanisms and Animal Models of SARS-CoV-2 Infection , 2021, Frontiers in Cell and Developmental Biology.

[3]  Andrew L. Phillips,et al.  Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[4]  A. Ward,et al.  One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization , 2021, bioRxiv.

[5]  D. Ho,et al.  Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates , 2021, bioRxiv.

[6]  Laura E. Crowell,et al.  Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters , 2021, bioRxiv.

[7]  I. Wilson,et al.  Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates , 2021, Science Advances.

[8]  Baoying Huang,et al.  Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice , 2021, Cellular & molecular immunology.

[9]  Stephanie S. Chen,et al.  Emergence of a Novel SARS-CoV-2 Variant in Southern California. , 2021, JAMA.

[10]  R. Fåhraeus,et al.  Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages , 2021, Biomolecules.

[11]  Elisabeth Mahase.  Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant , 2021, BMJ.

[12]  K. Kupferschmidt.  New mutations raise specter of 'immune escape'. , 2021, Science.

[13]  M. Nussenzweig,et al.  Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice , 2020, Science.

[14]  Jonathan L. Schmid-Burgk,et al.  COVID-19 Bibliometrics 8 th – 14 th February 2021 , 2021 .

[15]  W. Chiu,et al.  A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice , 2021, ACS central science.

[16]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[17]  D. Qu,et al.  RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response , 2020, Signal Transduction and Targeted Therapy.

[18]  Xin He,et al.  Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses , 2020, Immunity.

[19]  Elisabeth Mahase.  Covid-19: What do we know about the late stage vaccine candidates? , 2020, BMJ.

[20]  J. Pollet,et al.  Recombinant protein vaccines, a proven approach against coronavirus pandemics , 2020, Advanced Drug Delivery Reviews.

[21]  S. Perlman,et al.  COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.

[22]  D. Schneidman-Duhovny,et al.  Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 , 2020, Science.

[23]  S. Ladhani,et al.  Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection , 2020, bioRxiv.

[24]  Lisa E. Gralinski,et al.  Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 , 2020, Cell.

[25]  L. Zentilin,et al.  Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology , 2020, EBioMedicine.

[26]  H. Rammensee,et al.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition , 2020, Nature immunology.

[27]  K. Sauer,et al.  An Effective COVID-19 Vaccine Needs to Engage T Cells , 2020, Frontiers in Immunology.

[28]  E. Aronica,et al.  Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study , 2020, The Lancet Microbe.

[29]  R. Owens,et al.  A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses , 2020, Nature Communications.

[30]  D. Irvine,et al.  Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo , 2020, Immunity.

[31]  Ralf Bartenschlager,et al.  Structures and distributions of SARS-CoV-2 spike proteins on intact virions , 2020, Nature.

[32]  T. Solomon,et al.  Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays , 2020, The Journal of infectious diseases.

[33]  S. Munro,et al.  Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion , 2020, bioRxiv.

[34]  Shuwen Liu,et al.  Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.

[35]  Zeyu Chen,et al.  T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.

[36]  Yuquan Wei,et al.  A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.

[37]  D. Matthews,et al.  Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein , 2020, Genome Medicine.

[38]  S. Klein,et al.  Considering how biological sex impacts immune responses and COVID-19 outcomes , 2020, Nature Reviews Immunology.

[39]  M. Malim,et al.  Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings , 2020, medRxiv.

[40]  S. Klein,et al.  Biological sex impacts COVID-19 outcomes , 2020, PLoS pathogens.

[41]  L. Stamatatos,et al.  Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual , 2020, bioRxiv.

[42]  S. Klein,et al.  Clinical trials for COVID-19 should include sex as a variable. , 2020, The Journal of clinical investigation.

[43]  Fang Li,et al.  Cell entry mechanisms of SARS-CoV-2 , 2020, Proceedings of the National Academy of Sciences.

[44]  Jiajia Xie,et al.  Biochemical characterization of SARS-CoV-2 nucleocapsid protein , 2020, Biochemical and Biophysical Research Communications.

[45]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[46]  D. Cucinotta,et al.  WHO Declares COVID-19 a Pandemic , 2020, Acta bio-medica : Atenei Parmensis.

[47]  M. Pal,et al.  Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update , 2020, Cureus.

[48]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[49]  D. Stuart,et al.  Lentiviral transduction of mammalian cells for fast, scalable and high-level production of soluble and membrane proteins , 2018, Nature Protocols.

[50]  J. Andersen,et al.  TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination , 2018, Proceedings of the National Academy of Sciences.

[51]  M. Howarth,et al.  Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination , 2018, ACS nano.

[52]  Karl D. Brune,et al.  New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue , 2018, Front. Immunol..

[53]  David Baker,et al.  Design of a hyperstable 60-subunit protein icosahedron , 2016, Nature.

[54]  D. Klenerman,et al.  Initiation of T cell signaling by CD45 segregation at ‘close-contacts’ , 2016, Nature Immunology.

[55]  B. Zakeri,et al.  Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin , 2012, Proceedings of the National Academy of Sciences.

[56]  Weixian Lu,et al.  A time- and cost-efficient system for high-level protein production in mammalian cells. , 2006, Acta crystallographica. Section D, Biological crystallography.

[57]  B. Wiedenheft,et al.  Structure of the DPS-like protein from Sulfolobus solfataricus reveals a bacterioferritin-like dimetal binding site within a DPS-like dodecameric assembly. , 2006, Biochemistry.

[58]  J. Morecroft,et al.  Radionuclide ejection fraction , 1988, The British journal of surgery.

[59]  S. Davis,et al.  Glycan Remodeling with Processing Inhibitors and Lectin-Resistant Eukaryotic Cells. , 2015, Methods in molecular biology.